NYSE:CO - Global Cord Blood Stock Price, Forecast & News

Global Cord Blood trades on the New York Stock Exchange (NYSE) under the ticker symbol "CO."

Global Cord Blood Corp (NYSE:CO) announced its quarterly earnings data on Tuesday, November, 26th. The medical research company reported $0.14 earnings per share (EPS) for the quarter. The medical research company earned $43.86 million during the quarter. Global Cord Blood had a net margin of 34.86% and a return on equity of 10.88%. View Global Cord Blood's Earnings History.

Global Cord Blood is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Global Cord Blood.

News stories about CO stock have trended somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Global Cord Blood earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Global Cord Blood.

Global Cord Blood saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 57,300 shares, an increase of 38.1% from the December 15th total of 41,500 shares. Based on an average daily volume of 63,900 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.2% of the shares of the stock are short sold. View Global Cord Blood's Current Options Chain.

Some companies that are related to Global Cord Blood include Verra Mobility (VRRM), Bain Capital Specialty Finance (BCSF), GS ACQUISITION /SH CL A (GSAH), HAYMAKER ACQUIS/SH CL A (HYAC), Trinity Merger (TMCX), AdaptHealth (AHCO), Pivotal Acquisition (PVT), FORUM MERGER II/SH CL A (FMCI), Kaleyra (KLR), ANDINA ACQUISIT/SH SH (ANDA), Opes Acquisition (OPES), AgroFresh Solutions (AGFS), KBL MERGER CORP/SH (KBLM), Infrastructure and Energy Alternatives (IEA) and Pensare Acquisition (WRLS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Cord Blood investors own include Fate Therapeutics (FATE), Spero Therapeutics (SPRO), AbbVie (ABBV), Rite Aid (RAD), NovaBay Pharmaceuticals (NBY), Galectin Therapeutics (GALT), Gilead Sciences (GILD), Intel (INTC), Marvell Technology Group (MRVL) and Vertex Pharmaceuticals (VRTX).

Shares of CO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CO stock can currently be purchased for approximately $5.00.

Global Cord Blood has a market capitalization of $607.76 million and generates $147.03 million in revenue each year. Global Cord Blood employs 1,261 workers across the globe.View Additional Information About Global Cord Blood.

The official website for Global Cord Blood is http://www.globalcordbloodcorp.com/.

Global Cord Blood's mailing address is 48 FL. BANK OF CHINA TOWER 1 GARDEN ROAD, HONG KONG K3, . The medical research company can be reached via phone at 852-3605-8180 or via email at [email protected]